Tirabrutinib vs placebo for CNS lymphoma in remission
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether taking the drug tirabrutinib (a pill) can help keep primary CNS lymphoma from coming back after successful initial chemotherapy. It compares the drug to a placebo (a dummy pill).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called B cell lymphoma that started in your brain or spinal cord.
- You are at least 18 years old.
- Your first chemotherapy (which included methotrexate) worked well, and a scan shows no signs of lymphoma now.
- You have not had radiation to the brain for this cancer and do not plan to.
- You have not taken a BTK inhibitor before (the study drug is a BTK inhibitor).
- Your blood counts and organ function are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.